(“Ananda” or the “Company”)
Hapac® update and Grant of Options
The Directors of Ananda are pleased to provide shareholders with the following update on the Company’s activities.
HAPAC UPDATE AND INTERNATIONAL OPPORTUNITIES
Hapac® is a dry herb medical cannabis inhalation system which was launched in various retail outlets in
After feedback from customers in the early months of 2019, hapac® made some changes to its offering. It introduced three different herb blends to its range and made some small technical changes to the hapac® vaping device in order to reduce the pressure drop experienced at inhalation. The Directors have been advised that these changes were well received, with growth in sales and the commencement of repeat sales. May and June hapac® device sales were 33 and 29 respectively and sales of hapac® sachets were 596 and 628 during the same period. Online sales of hapac® also commenced through the website haplondon.com.
Although sales of hapac® commenced in
Notwithstanding the above, LHT believes it has achieved proof of concept of the hapac® system and will now commence the launch of hapac® in other international markets. This is in line with its original plans. LHT has signed an agreement with Cannabis Innovation Finder (CIF) to assess the appetite for hapac® in Canada. CIF is a
Further information on hapac® can be found at hapac.tech.
GRANT OF OPTIONS
In light of Dr Schmell’s contribution to the Company, the Directors have approved the issue to
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC+44 (0)7717 573 235 Chief Executive Officer email@example.com Melissa SturgessInvestor Relations Jeremy Sturgess-SmithPETERHOUSE CAPITAL LIMTED +44 (0)20 7469 0930 Corporate Finance Mark Anwyl Allie FeuerleinCorporate Broking Lucy Williams Duncan VaseySTANFORD CAPITAL PARTNERS LIMITED +44 (0)20 3815 8880 Joint Corporate Broker John Howes Patrick ClaridgeCELICOURT COMMUNICATIONS +44 (0)20 7520 9266 Mark Antelme Ollie Mills
Ananda Developments currently has three key areas of endeavour. They include its interest in iCAN, a global leader in medicinal cannabis research and a recognized thought leader in the space; its 15% shareholding in Liberty Herbal Technologies which is the owner of the recently launched hapac® technology for the dry vaping of medicinal cannabis; and its 100% ownership of
A copy of the Company’s Admission Document is available at www.anandadevelopments.com/wp- content/uploads/2019/03/ANANDA-DEVELOPMENTS-Admission-Document-29.06.2018-FINAL- clean.pdf
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 Details of the person discharging managerial responsibilities / person closely associated a)
NameDr. Eli David Schmell, PhD. 2 Reason for the notification a) Position/status Senior Investment Adviser b) Initial notification /Amendment Initial 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Ananda Developments plcb) LEI 894500DFM8VOC5FW4X47 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary shares of 0.2p each Identification code ISIN: GB00BDQPXQ60 b) Nature of the transaction Grant of options c) Price(s) and volume(s) 6,300,000 Ordinary Shares at an exercise price of £0.0045 per share d) Aggregated information - Aggregated volume - Price N/A e) Date of the transaction 17 September 2019f) Place of the transaction Outside a trading venue
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a